Evaluation of Everolimus Activity against <i>Mycobacterium tuberculosis</i> Using In Vitro Models of Infection
Even though Everolimus has been investigated in a phase II randomized trial as a host-directed therapy (HDT) to treat tuberculosis (TB), an oncological patient treated with Everolimus for a neuroendocrine pancreatic neoplasia developed active TB twice and a non-tuberculous mycobacterial (NTM) infect...
Main Authors: | Delia Mercedes Bianco, Flavio De Maio, Giulia Santarelli, Ivana Palucci, Alessandro Salustri, Giada Bianchetti, Giuseppe Maulucci, Franco Citterio, Maurizio Sanguinetti, Enrica Tamburrini, Michela Sali, Giovanni Delogu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/12/1/171 |
Similar Items
-
Effects of Everolimus in Modulating the Host Immune Responses against <i>Mycobacterium tuberculosis</i> Infection
by: Anmol Raien, et al.
Published: (2023-11-01) -
Two cases of eczematous eruptions caused by everolimus
by: Minako Habu, et al.
Published: (2019-10-01) -
Antimycobacterial Effects of Everolimus in a Human Granuloma Model
by: David Ashley, et al.
Published: (2020-06-01) -
Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus
by: Eui Joo Kim, et al.
Published: (2020-11-01) -
Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
by: Saira Justin, et al.
Published: (2020-06-01)